Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand ?

Cited by papers we hold 2

• ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? · 2017
  No notice
• ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.